会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 83. 发明申请
    • N-PHENYL-LACTAM DERIVATIVES CAPABLE OF STIMULATING NEUROGENESIS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
    • 刺激神经细胞的N-PHENYL-LACTAM衍生物及其在治疗神经疾病中的应用
    • WO2015107053A1
    • 2015-07-23
    • PCT/EP2015/050521
    • 2015-01-14
    • F. HOFFMANN-LA ROCHE AGHOFFMANN-LA ROCHE INC.
    • JAKOB-ROETNE, RolandWICHMANN, JuergenPETERS, Jens-UweJAGASIA, Ravi
    • C07D401/10A61K31/4155A61K31/4178A61K31/422A61K31/4439A61K31/513C07D403/10C07D413/10A61P25/00
    • C07D413/10C07D401/10C07D401/14C07D403/10
    • The present invention relates to compounds of the general formula I wherein Het is oxazole-5-yl, pyridin-4-yl, or pyrazol-4-yl; R 1 / R 2 are, independently from each other, hydrogen, lower alkyl, lower alkoxy, or halogen; W is -CH 2 - or -CH 2 CH 2 -; X is CR 3 R 4 or NR 5 ; R 3 is hydrogen or lower alkyl; R 4 is -(CH 2 ) n -phenyl, optionally substituted by halogen, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or lower alkyl; R 5 is CHR-phenyl or CH2CHR-phenyl, optionally substituted by halogen, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or lower alkyl, or is CHR-pyridin-2, 3 or 4 -yl; R is hydrogen or lower alkyl; n is 0 or 1; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomer thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.
    • 本发明涉及通式I的化合物,其中Het是恶唑-5-基,吡啶-4-基或吡唑-4-基; R 1 / R 2彼此独立地为氢,低级烷基,低级烷氧基或卤素; W是-CH 2 - 或-CH 2 CH 2 - ; X是CR 3 R 4或NR 5; R3是氢或低级烷基; R4是 - (CH2)n-苯基,任选被卤素取代,低级烷氧基,被卤素取代的低级烷基,被卤素或低级烷基取代的低级烷氧基; R 5是CHR-苯基或CH 2 CHR-苯基,任选地被卤素,低级烷氧基,被卤素取代的低级烷基,被卤素或低级烷基取代的低级烷氧基取代,或是CHR-吡啶-2,3或4-基; R是氢或低级烷基; n为0或1; 或其药学上可接受的酸加成盐与外消旋混合物或其相应的对映异构体和/或其旋光异构体反应。 该化合物可用于治疗精神分裂症,强迫症人格障碍,抑郁症,双相障碍,焦虑症,正常老化,癫痫,视网膜变性,创伤性脑损伤,脊髓损伤,创伤后应激障碍,恐慌症, 帕金森病,痴呆,阿尔茨海默氏病,认知障碍,化学疗法诱导的认知功能障碍,唐氏综合征,自闭症谱系障碍,听力损失,耳鸣,脊髓小脑性共济失调,肌萎缩性侧索硬化,多发性硬化,亨廷顿病,中风,放射治疗,慢性应激, 滥用神经活性药物,选自酒精,阿片剂,甲基苯丙胺,苯环利定和可卡因。